Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CT-868 | Experimental | SC dose of CT-868 Intervention: Drug: CT-868 |
|
| Placebo | Placebo Comparator | SC dose of placebo matching CT-868 dose Intervention: Drug: Placebo |
|
| Active Comparator | Active Comparator | SC dose of Active Comparator Intervention: Drug: Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CT-868 as SC Injection | Drug | CT-868 |
| |
| Placebo as SC Injection |
| Measure | Description | Time Frame |
|---|---|---|
| Change in insulin secretion rate and ambient glucose levels | Baseline up to 4 days |
| Measure | Description | Time Frame |
|---|---|---|
| Change in blood insulin levels at each level of glucose infusion | Baseline up to 4 days | |
| Change in blood glucose levels at each level of glucose infusion | Baseline up to 4 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Carmot Therapeutics, Inc., a member of the Roche Group | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Carmot Clinical Research Unit 101 | Chula Vista | California | 91911 | United States |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D003924 | Diabetes Mellitus, Type 2 |
| D050177 | Overweight |
| D008659 | Metabolic Diseases |
| D001835 | Body Weight |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D044343 | Overnutrition |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Placebo |
|
| Active Comparator as SC Injection | Drug | Active Comparator |
|
| D009748 | Nutrition Disorders |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |